These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31668021)

  • 1. Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.
    Abrantes JA; Solms A; Garmann D; Nielsen EI; Jönsson S; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):894-903. PubMed ID: 31668021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.
    McEneny-King A; Chelle P; Foster G; Keepanasseril A; Iorio A; Edginton AN
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):411-426. PubMed ID: 31104228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.
    Abrantes JA; Solms A; Garmann D; Nielsen EI; Jönsson S; Karlsson MO
    Haematologica; 2020 May; 105(5):1443-1453. PubMed ID: 31371418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of prophylaxis for hemophilia A.
    Herbert RD; Broderick CR; Barnes C; Billot L; Zhou A; Latimer J
    PLoS One; 2018; 13(2):e0192783. PubMed ID: 29447219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
    Nagao A; Yeung CHT; Germini F; Suzuki T
    Thromb Res; 2019 Jan; 173():79-84. PubMed ID: 30496937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.
    Abrantes JA; Jönsson S; Karlsson MO; Nielsen EI
    Br J Clin Pharmacol; 2019 Jun; 85(6):1326-1336. PubMed ID: 30767254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
    Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
    Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
    Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
    Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
    Tegenge MA; Yang H; Forshee RA
    Haemophilia; 2017 Sep; 23(5):705-711. PubMed ID: 28543946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
    Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH;
    Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
    Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
    Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII half-life and clinical phenotype of severe hemophilia A.
    van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
    Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.
    Tiede A; Abdul Karim F; Jiménez-Yuste V; Klamroth R; Lejniece S; Suzuki T; Groth A; Santagostino E
    Haematologica; 2021 Jul; 106(7):1902-1909. PubMed ID: 32327501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.